Tilray | TRLY - Equity Capital And Reserves


Tilray reported $1.58B in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Acasti Pharma USD 64.89M 2.07M Dec/2025
Akebia Therapeutics USD 27.38M 5.24M Mar/2026
Alaunos Therapeutics USD 1.29M 865K Mar/2026
Aurora Cannabis CAD 511.83M 24.53M Mar/2026
Avita Medical AUD -16.65M 3.76M Dec/2025
Canopy Growth CAD 697.59M 60.58M Mar/2026
Cronos Group USD 1.07B 20.24M Mar/2026
Dianthus Therapeutics USD 1.2B 707.91M Mar/2026
Divis Laboratories Ltd INR 167.61B 13.48B Mar/2026
Ionis Pharmaceuticals USD 491.41M 2.32M Mar/2026
IQVIA Holdings USD 6.22B 282M Mar/2026
Knight Therapeutics CAD 767.27M 480K Dec/2025
Moderna USD 7.41B 1.24B Mar/2026
Organigram Holdings CAD 371.81M 2.36M Mar/2026
Organon & Co USD 903M 151M Mar/2026
Revvity USD 7.25B 125.54M Dec/2025
Tectonic Therapeutic USD 230.42M 20.91M Mar/2026
Tilray USD 1.58B 39.08M Sep/2025
Viatris USD 14.66B 53.6M Mar/2026
Xeris Pharmaceuticals USD 13.01M 678K Mar/2026
Zealand Pharma A/S 14.83B 331.99M Dec/2025